Spots Global Cancer Trial Database for relapsed refractory multiple myeloma
Every month we try and update this database with for relapsed refractory multiple myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody | NCT03525678 | Multiple Myelom... | Belantamab mafo... Belantamab mafo... | 18 Years - | GlaxoSmithKline | |
| Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | NCT05308225 | Multiple Myelom... | STI-6129 | 18 Years - | Sorrento Therapeutics, Inc. | |
| Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients | NCT01002248 | Multiple Myelom... | Perifosine Perifosine Plac... Bortezomib Dexamethasone | 18 Years - | AEterna Zentaris | |
| AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma | NCT06106945 | Multiple Myelom... | AZD0305 | 18 Years - | AstraZeneca | |
| Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | NCT01962792 | Multiple Myelom... | Ibrutinib Carfilzomib Dexamethasone | 18 Years - | Pharmacyclics LLC. | |
| Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma | NCT03934684 | Relapsed Refrac... | Drug: Carfilzom... Drug: Carfilzom... | 18 Years - | Amgen | |
| Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | NCT04505813 | Relapsed Refrac... | NEXI-002 T Cell... | 18 Years - | NexImmune Inc. | |
| Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma | NCT00452569 | Multiple Myelom... | Thalidomide Dexamethasone | 18 Years - | Celgene | |
| First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone | NCT04075721 | Multiple Myelom... | M3258 M3258 20 mg | 18 Years - | EMD Serono | |
| Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | NCT02548962 | Multiple Myelom... | Ibrutinib Pomalidomide Dexamethasone Placebo | 18 Years - 100 Years | Pharmacyclics LLC. | |
| A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | NCT02963493 | Multiple Myelom... | Melphalan flufe... Dexamethasone | 18 Years - | Oncopeptides AB | |
| Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes | NCT06282978 | Multiple Myelom... | Elranatamab (PF... | 18 Years - | PETHEMA Foundation | |
| Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma | NCT01478581 | Multiple Myelom... | PCI-32765 Dexamethasone | 18 Years - | Pharmacyclics LLC. | |
| Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | NCT04505813 | Relapsed Refrac... | NEXI-002 T Cell... | 18 Years - | NexImmune Inc. | |
| Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma | NCT01478581 | Multiple Myelom... | PCI-32765 Dexamethasone | 18 Years - | Pharmacyclics LLC. | |
| Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | NCT02548962 | Multiple Myelom... | Ibrutinib Pomalidomide Dexamethasone Placebo | 18 Years - 100 Years | Pharmacyclics LLC. | |
| Myeloma-Developing Regimens Using Genomics (MyDRUG) | NCT03732703 | Relapsed Refrac... | Abemaciclib, de... Enasidenib, dex... Cobimetinib, de... Erdafitinib, de... Venetoclax, dex... Daratumumab, de... Belantamab mafo... Selinexor, dexa... | 18 Years - | Multiple Myeloma Research Consortium | |
| Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma | NCT01478581 | Multiple Myelom... | PCI-32765 Dexamethasone | 18 Years - | Pharmacyclics LLC. | |
| Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | NCT05308225 | Multiple Myelom... | STI-6129 | 18 Years - | Sorrento Therapeutics, Inc. | |
| A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | NCT02963493 | Multiple Myelom... | Melphalan flufe... Dexamethasone | 18 Years - | Oncopeptides AB | |
| Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT | NCT04150965 | Multiple Myelom... Relapsed Refrac... | Elotuzumab, pom... Anti-LAG-3 Anti-LAG-3 + Po... Anti-TIGIT Anti-TIGIT + Po... | 18 Years - | Multiple Myeloma Research Consortium | |
| Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) | NCT00633542 | Multiple Myelom... | thalidomide interferon alph... | 18 Years - | Università Politecnica delle Marche |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
